. Author manuscript; available in PMC: 2009 Aug 19.

Published in final edited form as: Vaccine. 2008 Aug 19;26(Suppl 10):K53–K61. doi: 10.1016/j.vaccine.2008.06.002

Table 5.

Immunogenicity bridging studies.

Study	Vaccine	Study Groups/Age years (N)	Serologic Assay	% Sero-conversion^a	Major Conclusions*
Reisinger KS et al. 2007 [12]	Gardasil®	Boys: 9-16 (567)	cLIA	≥99.5 for all types	GMTs for boys non-inferior to those in girls
Reisinger KS et al. 2007 [12]	Gardasil®	Girls: 9-15 (617)	cLIA	≥99.6 for all types	Boys GMT 1.1-1.5 fold higher than girls

Block SL et al. 2006 [26]	Gardasil®	Boys: 10-15 (510)	cLIA	≥99.7 for all types	GMTs for boys and girls non-inferior to those in women
		Girls: 10-15 (506)		100 for all types	Boys GMT 1.8-2.7 fold higher than women’s
		Women: 16-23 (513)		≥99.1 for all types	Girls GMT 1.7-2.0 fold higher than women’s

Pedersen C et al. 2007 [27]	Cervarix®	Girls: 10-14 (158)	ELISA	100 for both types	GMTs for girls non-inferior to those in women
Pedersen C et al. 2007 [27]	Cervarix®	Women: 15-25 (458)	ELISA	100 for both types	Girl’s GMT 2.1-2 fold higher than women’s

According to protocol (ATP) analyses one month after 3^rd vaccine dose.

cLIA: Chelated ligand internalization assay; ELISA: Enzyme linked immunosorbent assay; GMT: Geometric Mean Titer.

Sources of data: [12,26,27].